245 related articles for article (PubMed ID: 35628654)
21. New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines.
Klejewski A; Świerczewska M; Zaorska K; Brązert M; Nowicki M; Zabel M; Januchowski R
Anticancer Res; 2017 Apr; 37(4):1625-1636. PubMed ID: 28373423
[TBL] [Abstract][Full Text] [Related]
22. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer.
Liu MX; Siu MK; Liu SS; Yam JW; Ngan HY; Chan DW
Oncotarget; 2014 Feb; 5(4):944-58. PubMed ID: 24659709
[TBL] [Abstract][Full Text] [Related]
24. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
[TBL] [Abstract][Full Text] [Related]
25. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
Zou J; Yin F; Wang Q; Zhang W; Li L
Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
[TBL] [Abstract][Full Text] [Related]
26. New and Old Genes Associated with Primary and Established Responses to Cisplatin and Topotecan Treatment in Ovarian Cancer Cell Lines.
Świerczewska M; Klejewski A; Wojtowicz K; Brązert M; Iżycki D; Nowicki M; Zabel M; Januchowski R
Molecules; 2017 Oct; 22(10):. PubMed ID: 29027969
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of miR-138-5p Sensitizes Taxol-Resistant Epithelial Ovarian Cancer Cells through Targeting Cyclin-Dependent Kinase 6.
Liang M; Li Q; Shi S; Tian YN; Feng Y; Yang Y; Dong M; Zhang J; He J
Gynecol Obstet Invest; 2021; 86(6):533-541. PubMed ID: 34818258
[TBL] [Abstract][Full Text] [Related]
28. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
29. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells.
Miyamoto M; Sawada K; Nakamura K; Yoshimura A; Ishida K; Kobayashi M; Shimizu A; Yamamoto M; Kodama M; Hashimoto K; Kimura T
Sci Rep; 2020 Oct; 10(1):16755. PubMed ID: 33028939
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA expression profiles associated with development of drug resistance in Ehrlich ascites tumor cells.
Husted S; Søkilde R; Rask L; Cirera S; Busk PK; Eriksen J; Litman T
Mol Pharm; 2011 Dec; 8(6):2055-62. PubMed ID: 21899346
[TBL] [Abstract][Full Text] [Related]
32. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
33. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
[TBL] [Abstract][Full Text] [Related]
34. miRNA expression patterns in chemoresistant breast cancer tissues.
Lv J; Xia K; Xu P; Sun E; Ma J; Gao S; Zhou Q; Zhang M; Wang F; Chen F; Zhou P; Fu Z; Xie H
Biomed Pharmacother; 2014 Oct; 68(8):935-42. PubMed ID: 25451164
[TBL] [Abstract][Full Text] [Related]
35. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
Tuncer SB; Erdogan OS; Erciyas SK; Saral MA; Celik B; Odemis DA; Turkcan GK; Yazici H
J Ovarian Res; 2020 Aug; 13(1):99. PubMed ID: 32854743
[TBL] [Abstract][Full Text] [Related]
36. Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells-A Preliminary Study.
Mizielska A; Dziechciowska I; Szczepański R; Cisek M; Dąbrowska M; Ślężak J; Kosmalska I; Rymarczyk M; Wilkowska K; Jacczak B; Totoń E; Lisiak N; Kopczyński P; Rubiś B
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980974
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA Expression Profiling of Epithelial Ovarian Cancer Identifies New Markers of Tumor Subtype.
Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
Microrna; 2020; 9(4):289-294. PubMed ID: 32703147
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
39. Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.
Ricci JW; Lovato DM; Severns V; Sklar LA; Larson RS
Mol Cancer Ther; 2016 Dec; 15(12):2853-2862. PubMed ID: 27671528
[TBL] [Abstract][Full Text] [Related]
40. High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer.
Rattanapan Y; Korkiatsakul V; Kongruang A; Siriboonpiputtana T; Rerkamnuaychoke B; Chareonsirisuthigul T
Microrna; 2021; 10(1):51-57. PubMed ID: 33845755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
